Janus Henderson Group PLC lessened its holdings in shares of Humana Inc (NYSE:HUM) by 0.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,289,802 shares of the insurance provider’s stock after selling 18,078 shares during the period. Humana makes up approximately 0.6% of Janus Henderson Group PLC’s portfolio, making the stock its 19th biggest holding. Janus Henderson Group PLC owned 2.39% of Humana worth $1,113,646,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Stratos Wealth Partners LTD. purchased a new stake in Humana during the third quarter worth $108,000. Sun Life Financial INC lifted its position in shares of Humana by 120.7% in the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after acquiring an additional 204 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Humana by 2,984.6% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 388 shares in the last quarter. Smithfield Trust Co. lifted its position in Humana by 531.2% during the third quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock worth $165,000 after buying an additional 409 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Humana by 64.6% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 512 shares of the insurance provider’s stock worth $173,000 after buying an additional 201 shares during the period. 93.05% of the stock is currently owned by hedge funds and other institutional investors.

In other Humana news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the sale, the chief executive officer now owns 71,085 shares in the company, valued at approximately $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Roy A. Beveridge sold 4,622 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the sale, the insider now owns 10,621 shares of the company’s stock, valued at approximately $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is owned by company insiders.

HUM stock opened at $319.73 on Monday. Humana Inc has a 1 year low of $231.90 and a 1 year high of $355.88. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $43.86 billion, a PE ratio of 27.30, a P/E/G ratio of 1.52 and a beta of 1.03.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. Humana had a return on equity of 19.10% and a net margin of 2.70%. The firm had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. During the same quarter last year, the firm earned $3.39 EPS. Equities analysts predict that Humana Inc will post 14.43 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, December 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.63%. Humana’s dividend payout ratio (DPR) is presently 17.08%.

Several equities research analysts have commented on the company. MED upped their price target on Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research note on Thursday, November 8th. Royal Bank of Canada increased their target price on Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research note on Thursday, November 8th. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Bank of America increased their target price on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Finally, Credit Suisse Group increased their target price on Humana from $370.00 to $390.00 and gave the company an “outperform” rating in a research note on Thursday, November 8th. Seven analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $352.30.

WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/humana-inc-hum-position-trimmed-by-janus-henderson-group-plc.html.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: Do You Need a Fiduciary?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.